Related Experiment Videos
Angiosarcoma of the face and scalp
Abstract:
Angiosarcomas of the face and scalp are aggressive, malignant neoplasms that are associated with a poor prognosis. Radiotherapy and chemotherapy alone have failed to give satisfactory results in the treatment of this disease, so surgery continues to play the major role in its management. In this article we report on 3 patients with angiosarcoma of the face and scalp recently seen in our institution. The clinical presentation, pathophysiology, and prognosis are extensively reviewed from the recent literature. We conclude with a discussion of treatment options in the management of this disease, with emphasis on surgical management.
Insights
Aggressive angiosarcomas of the face and scalp have a poor prognosis. Surgical management offers the most promising treatment option for this rare cancer, despite challenges with radiotherapy and chemotherapy.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatopathology
Background:
- Angiosarcomas of the face and scalp are rare, aggressive vascular neoplasms.
- These tumors are associated with a poor prognosis and high recurrence rates.
- Conventional treatments like radiotherapy and chemotherapy often yield unsatisfactory results.
Observation:
- This article presents three recent cases of angiosarcoma of the face and scalp managed at our institution.
- Detailed clinical presentations and pathological findings of these cases are discussed.
- The review emphasizes the challenges in diagnosing and treating these rare malignancies.
Findings:
- Surgical management remains the cornerstone for treating angiosarcomas of the face and scalp.
- Multidisciplinary approaches are crucial for optimizing patient outcomes.
- Early diagnosis and aggressive surgical resection are key to improving prognosis.
Implications:
- The findings highlight the critical role of surgical expertise in managing these aggressive tumors.
- Further research into targeted therapies and adjuvant treatments is warranted.
- Improved understanding of angiosarcoma pathophysiology may lead to novel therapeutic strategies.